Travere Therapeutics expanded its rare kidney disease pipeline in a deal with Everest Medicines, licensing civorebrutinib for development and commercialization outside China and parts of East and Southeast Asia. The structure includes a $112.5 million upfront payment to Everest, plus up to $1.03 billion in milestone payments and royalties. Travere is positioning the oral, covalent reversible BTK inhibitor for immune-mediated kidney indications, starting with primary membranous nephropathy where Everest has produced proof-of-concept data. The deal lands shortly after Travere won FDA approval for a second indication for Filspari (sparsentan), underscoring the company’s push to build beyond its approved rare kidney franchise.